Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo- β-lactamase-producing Klebsiella pneumoniae infections

Metallo- β-lactamase (MBL)-producingKlebsiella pneumoniae (Kp) is increasingly reported in Europe and the United States, and limited treatment options are available against this superbug.1 –6 MBLs hydrolyse all β-lactams except aztreonam, but this latter cannot be used as monotherapy because of the co-production of expanded-spectrum-β-lactamases (ESBL). Novel β-lactam/β-lactamase inhibitors (BLBLIs), including ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam, are inactive against MB L-producing Enterobacterales. The combination ceftazidime/avibactam plus aztreonam displaysin vitro synergy and has been associated with lower mortality rate compared with colistin in patients with bloodstream infections by MBL-producing Enterobacterales.7 Limited data about the combination of aztreonam plus other BLBLIs are available.8 –10
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research